NASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $62.40 -0.73 (-1.16%) Closing price 04:00 PM EasternExtended Trading$62.38 -0.02 (-0.03%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About CG Oncology Stock (NASDAQ:CGON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CG Oncology alerts:Sign Up Key Stats Today's Range$61.52▼$63.8550-Day Range$62.38▼$80.6852-Week Range$35.80▼$80.97Volume1.19 million shsAverage Volume1.08 million shsMarket Capitalization$5.53 billionP/E RatioN/ADividend YieldN/APrice Target$87.50Consensus RatingModerate Buy Company Overview CG Oncology, Inc. (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on developing therapies for bladder cancer and other cancers of the urinary tract. The company’s research centers on cancer-directed immunotherapies designed to stimulate the immune system and target tumor cells. Its lead product candidate is cretostimogene grenadenorepvec, an intravesical oncolytic adenovirus being studied for the treatment of non-muscle-invasive bladder cancer (NMIBC). The therapy is designed to be delivered directly into the bladder, where it may selectively infect tumor cells and activate an immune response against cancer. CG Oncology has evaluated cretostimogene in clinical studies involving patients with NMIBC, including individuals whose disease has not responded adequately to Bacillus Calmette-Guérin (BCG), a standard bladder cancer treatment. The company’s development efforts have included studies of different NMIBC patient populations and treatment settings. CG Oncology is headquartered in California and has focused its operations primarily on advancing its oncology pipeline through clinical development.AI Generated. May Contain Errors. Read More CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreCGON MarketRank™: 3.66714982211 of 5 starsCG Oncology scored higher than 73% of companies evaluated by MarketBeat, and ranked 123rd out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCG Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCG Oncology has a consensus price target of $87.50, representing about 40.2% upside from its current price of $62.40.Amount of Analyst CoverageCG Oncology has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CG Oncology are expected to grow in the coming year, from ($3.31) to ($3.12) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -23.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -23.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 6.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CG Oncology's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted12.37% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.46.Change versus previous monthShort interest in CG Oncology has recently decreased by 7.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. News and Social Media3.5 / 5News Sentiment0.55 News SentimentCG Oncology has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for CG Oncology this week, compared to 4 articles on an average week.Search Interest4 people have searched for CGON on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows5 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $147,520.00 in company stock.Percentage Held by Insiders4.80% of the stock of CG Oncology is held by insiders.Percentage Held by Institutions26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CGON Stock News HeadlinesCG Oncology, Inc. Appoints Isabel Kalofonos as Chief Commercial Officer14 minutes ago | marketscreener.comMCG Oncology Inc CGON14 minutes ago | morningstar.comMReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 13 at 1:00 AM | Base Camp Trading (Ad)How Investors May Respond To CG Oncology (CGON) Hiring a CCO Before Potential Bladder Cancer Launch14 minutes ago | finance.yahoo.comCG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial OfficerOctober 13 at 8:00 AM | globenewswire.comCG Oncology (NASDAQ:CGON) and Myriad Genetics (NASDAQ:MYGN) Head-To-Head ReviewOctober 13 at 4:45 AM | americanbankingnews.comKuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmOctober 12 at 9:31 PM | prnewswire.comCG Oncology (NASDAQ:CGON) Director Sells 1,000 Shares of StockSeptember 18, 2026 | insidertrades.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $41.52 at the beginning of the year. Since then, CGON stock has increased by 50.3% and is now trading at $62.40. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) issued its earnings results on Thursday, August, 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.66) by $0.24. The company earned $1.16 million during the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative net margin of 3,602.68% and a negative trailing twelve-month return on equity of 25.20%. When did CG Oncology IPO? CG Oncology (CGON) raised $340 million in an initial public offering (IPO) on Thursday, January 25th 2024. The company issued 20,000,000 shares at $16.00-$18.00 per share. Who are CG Oncology's major shareholders? Top institutional shareholders of CG Oncology include GAMMA Investing LLC. Insiders that own company stock include Hong Fang Song, Brian Guan-Chyun Liu, Decheng Capital Global Life Sc, James Mulay, Corleen M Roche and Vijay Kasturi. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Micron Technology (MU), NVIDIA (NVDA), SoundHound AI (SOUN), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), Broadcom (AVGO) and Definium Therapeutics (DFTX). Company Calendar Last Earnings8/06/2026Today10/13/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (17m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 CGON's financial health is in the Green zone, according to TradeSmith. CGON has been in this zone for over 17 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone(949) 409-3700FaxN/AEmployees142Year Founded2010Price Target and Rating Average Price Target for CG Oncology$87.50 High Price Target$100.00 Low Price Target$79.00 Potential Upside/Downside+40.2%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160.99 million Net Margins-3,602.68% Pretax Margin-3,602.68% Return on Equity-25.20% Return on Assets-23.98% Debt Debt-to-Equity RatioN/A Current Ratio22.22 Quick Ratio22.20 Sales & Book Value Annual Sales$4.04 million Price / Sales1,369.09 Cash FlowN/A Price / Cash FlowN/A Book Value$9.33 per share Price / Book6.69Miscellaneous Outstanding Shares88,640,000Free Float84,385,000Market Cap$5.53 billion OptionableOptionable Beta0.28 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:CGON) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our Partners100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
